Related Experiment Video
Updated: Aug 14, 2025
13:36
Scalable Fluidic Injector Arrays for Viral Targeting of Intact 3-D Brain Circuits
Published on: January 21, 2010
14.5K
Summary
The U.S. federal spending bill for fiscal year 2023 allocates $1.7 trillion, increasing funding for the National Cancer Institute (NCI), National Institutes of Health (NIH), and Food and Drug Administration (FDA). Cancer research advocates seek larger NCI increases to boost research funding paylines.
Area of Science:
- Biomedical Research Funding
- Government Health Policy
- Cancer Research Investment
Background:
- The U.S. federal government enacted a $1.7 trillion spending bill for fiscal year 2023 in December.
- This bill includes funding increases of 5.6% to 6.5% for key health agencies: National Cancer Institute (NCI), National Institutes of Health (NIH), and Food and Drug Administration (FDA).
Purpose of the Study:
- To analyze the implications of the fiscal year 2023 federal spending bill on cancer research funding.
- To highlight the perspectives of cancer research advocates regarding the adequacy of the allocated increases.
Main Methods:
- Analysis of the federal spending bill's financial allocations for health agencies.
- Review of statements and goals from cancer research advocacy groups.
Main Results:
- The fiscal year 2023 spending bill provides increased funding for the NCI, NIH, and FDA.
- The NCI funding increase is viewed positively but deemed insufficient by advocates to meet its payline goals.
Conclusions:
- While the FY2023 funding increase is a positive step, it may not be enough to achieve the NCI's objective of raising its payline to the 15th percentile by 2025.
- Continued advocacy for increased investment in cancer research is crucial to accelerate scientific progress and achieve ambitious research goals.
